Neuroscience & Biobehavioral Reviews
October 1, 2025
Anna Vaslavski, Anna Harwood Gross, Salomon Israel et al.
1 citation
3,4-Methylenedioxmethamphetamine (MDMA) has been shown to enhance social cognition, partly through its effects on oxytocin, a neuropeptide involved in social cognition. Despite growing evidence linking MDMA to increased oxytocin levels, no study has systematically examined this relationship across different doses, times, and participant characteristics. This systematic review and meta-analysis...
Journal of the American Society of Nephrology
October 1, 2025
Solabomi Oyeronke Ojeniyi, Christopher G. Shackleford, Sheetal Koul et al.
1 citation
Introduction: MDMA (3,4-methylenedioxymethamphetamine) toxicity can cause life-threatening complications, including hyperthermia, rhabdomyolysis, and acute kidney injury (AKI). While AKI from rhabdomyolysis is well known, C3 glomerulopathy (C3G) following MDMA use, to our knowledge, has not been reported. We present a case of oliguric AKI and biopsy-proven C3G after MDMA overdose. Case...
Frontiers in Psychiatry
September 26, 2025
Cato Grønnerød, Thea Rønningen, Ingrid Rike Haugsjå et al.
The purpose of the article: In recent years, a renewed interest has emerged in investigating the use of MDMA in the treatment of mental disorders. However, knowledge about the characteristics of recreational use of MDMA, its contexts and effects are limited. Methods: We recruited adult Norwegian participants aged 18 to 65 who reported having had a memorable experience after using MDMA. They...
Revista Neurociências
September 25, 2025
Vinícius Nascimento Cavalcante Da Silva, Gisele Ferreira de Freitas, Julia Martins de Lima Moscatelli et al.
Introdução. Este trabalho investiga o potencial terapêutico do MDMA (N-Metil-3,4-Metilenodioxianfetamina) no tratamento do Transtorno Depressivo, condição psiquiátrica caracterizada por humor deprimido persistente e anedonia. A pesquisa parte da limitação dos tratamentos tradicionais, como os inibidores seletivos da recaptação da serotonina (ISRSs), que apresentam resposta lenta, podendo levar...
Journal of Psychopharmacology
September 16, 2025
Ramona L. Martinez, Nina Radošić, Hanna Molla et al.
1 citation
Our findings extend previous research by demonstrating that MDMA increases feelings of trust in the social world beyond lab-specific interaction partners. These findings are consistent with user reports of generalized social well-being effects and support the idea that MDMA may have clinical value from a social psychological perspective.
Mental Health Weekly
September 15, 2025
Valerie A. Canady
In a historic move toward transparency, the U.S. Food and Drug Administration (FDA) on Sept. 4 publicly released its Complete Response Letter (CRL) rejecting the approval of midomafetamine (MDMA)‐assisted therapy for post‐traumatic stress disorder (PTSD). The letter, sent to Lykos Therapeutics in August 2024, outlines concerns about treatment durability, study design and prior MDMA use among...
Drug and Alcohol Dependence
September 12, 2025
Matthijs Blankers, Ruben Van Beek, Desirée Spronk et al.
1 citation
There is a lack of understanding of the nature of the post-acute affective response in the days after ecstasy/3,4-Methylenedioxymethamphetamine (MDMA) use and whether this is associated with ecstasy/MDMA use or circumstantial factors. In the three days following ecstasy/MDMA use, we evaluated whether a drop in mental well-being is observed and can be related to ecstasy use. Data for this study...
Research Square
September 12, 2025
Christina Chwyl, Angelica Spata, Will Lucas et al.
preprint
Abstract Background Self-transcendent and mystical experiences may be key mechanisms underlying psychedelics’ therapeutic effects, yet how these experiences differ across substances remains unclear. This study compared mystical and self-transcendent experiences across psilocybin, 3,4-Methylenedioxymethamphetamine (MDMA), and cannabis in a diverse, community-based sample, while accounting for...
September 7, 2025
Mathew Herbert, Brian H. Blanco, Dimitri Perivoliotis et al.
preprint
There is promise for 3,4-Methylenedioxymethamphetamine (MDMA)-assistedpsychotherapy as a highly effective and durable treatment for posttraumatic stress disorder(PTSD). However, the Food and Drug Administration rejected MDMA-assisted psychotherapy inits current form, expressing concerns about the lack of standardization and empirical basis ofpsychotherapy methods. This highlights the need to...
Frontiers in Psychiatry
September 5, 2025
Nicholas J. Ahari, Gregory A. Fonzo
3,4-methelenedioxymethamphetamine (MDMA) can be effective in treating posttraumatic stress disorder (PTSD) in controlled trials, potentially secondary to MDMA’s effects on neural circuits implicated in fear and reward. Although anxiety, stress, and fear-based disorders involve maladaptation of the neural circuits processing fear, threat, and reward, no studies have tested MDMA’s therapeutic...